BJA Advance Access originally published online on August 16, 2006
British Journal of Anaesthesia 2006 97(4):476-481; doi:10.1093/bja/ael205
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Predicting response to recombinant factor VIIa in non-haemophiliac patients with severe haemorrhage
1 Department of Haematology, Addenbrooke's Hospital Cambridge CB2 2QQ, UK
2 Department of Surgery, Addenbrooke's Hospital Cambridge CB2 2QQ, UK
3 John Farman Intensive Care Unit, Addenbrooke's Hospital Cambridge CB2 2QQ, UK
*Corresponding author: John Farman Intensive Care Unit, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, UK. E-mail: gilbertpark{at}doctors.org.uk
Background. Despite increasing use of recombinant factor VIIa (rFVIIa) in non-haemophiliac patients, it is unclear when rFVIIa might be effective.
Methods. A single centre review of consecutive non-haemophiliac patients receiving rFVIIa for the management of severe haemorrhage. Treatments with rFVIIa were at a dose of 90 µg kg–1 repeated at three hourly intervals at the clinicians' discretion.
Results. Eighteen patients received rFVIIa. Six patients survived to discharge and 12 patients died in hospital. The median (range) Sequential Organ Failure Assessment (SOFA) score at the time of administration of rFVIIa for the group that survived was 8.0 (5–12) compared with the group that died 12.0 (7.0–14.0) (P=0.03). One of the patients who survived (17%) had organ failure at the time of rFVIIa administration compared with 11 of those who died (92%) (P=0.004). Fifteen patients survived long enough to consider a second dose of rFVIIa, one patient who survived to discharge needed more than one dose (1/6, 17%), compared with seven of those who later died in hospital (7/9, 78%) (P=0.04). The survivors had a significant reduction in blood product requirements after rFVIIa, while patients who died did not. Neither the prothrombin time nor the activated partial thromboplastin time before or after rFVIIa predicted survival.
Conclusions. High SOFA score and failure to respond to one adequate dose of rFVIIa appear to identify patients with poor prognosis. These observations may help in determining when rFVIIa treatment is likely to be futile.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. A. Alten, K. Benner, K. Green, B. Toole, N. M. Tofil, and M. K. Winkler Pediatric Off-label Use of Recombinant Factor VIIa Pediatrics, March 1, 2009; 123(3): 1066 - 1072. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-F. Hardy, S. Belisle, and P. Van der Linden Efficacy and Safety of Recombinant Activated Factor VII to Control Bleeding in Nonhemophiliac Patients: A Review of 17 Randomized Controlled Trials Ann. Thorac. Surg., September 1, 2008; 86(3): 1038 - 1048. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Pang and A. Donaldson Probable right atrial thrombus immediately after recombinant activated factor VII administration Br. J. Anaesth., August 1, 2007; 99(2): 221 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Pugh, R. Wenstone, K. M. Bowles, and G. R. Park Predicting response to recombinant factor VIIa in non-haemophiliac patients with severe haemorrhage Br. J. Anaesth., May 1, 2007; 98(5): 690 - 691. [Full Text] [PDF]
|
|
E-letters:
Read all E-letters
- factor VIIa
- Imrat S Sohanpal
- British Journal of Anaesthesia, 4 Oct 2006 [Full text]
- Recombinant FactorVIIa in non-haemophiliacs
- NEVIL P. HUTCHINSON, et al.
- British Journal of Anaesthesia, 15 Nov 2006 [Full text]